Zacks small cap research.

Nov 27, 2023 · On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) were presented at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) ( Lauko et al., 2023 ). The Phase 2 clinical trial enrolled 62 GBM patients (36 newly diagnosed and 26 ... We run some scenario analyses to evaluate the total cost of an entity acquiring Tenax. If an acquiror’s bid price was set at $1.00 per share, the estimated cost to acquire the company would be approximately $52 million. At $2.00 per share, the price increases to $131 million and at $3.00, $210 million. See exhibit below for details on the ...Zacks Premium Research for ZSCCX View All Zacks Mutual Fund Rank #1's View the Zacks Mutual Fund Rank Guide Annual Return * 1 = Top 20%, 5 = Bottom 20% …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)Raises Gross Proceeds of $55 Million to Advance Lead Compound to Clinical Trials. On My 17, 2023, Satellos Biosciences Inc. (OTC:MSCLF) announced it closed an equity offering in which it raised gross proceeds of $55 million from the issuance of 110 million equity securities at $0.50 per common share or pre-funded warrant (70,297,220 common ...Investrade has good news to share - we are providing all customers FREE Snapshot research reports from Zacks Investment Research. There are reports on 4400 ...

Institutional Distribution. A 15-20 page, fully entitled research report, produced within 3-4 weeks that targets the institutional investor, currently distributed to First-Call, Capital IQ, Bloomberg, FactSet, and our own ZRS Platform. Together, these platforms target over 20,000 institutional investors and 90% of all asset and hedge fund managers.Aug 17, 2023 · The following slide gives an overview of the planned early stage clinical trials for CF-370 following submission of the IND, which we expect to occur in the third quarter of 2023. While a Phase 2 proof-of-concept trial is currently planned in patients with cystic fibrosis, the broad spectrum activity of CF-370 means it could likely be used for ...

When it comes to wheels, one small but important component that often goes unnoticed is the wheel center cap. These caps not only add a touch of style to your vehicle’s wheels but also serve several practical functions.Dec 22, 2022 · By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in total suffering from chronic allergic contact dermatitis (ACD) (NCT03680131). Zacks Small Cap Research. PLX: Back of the Envelope. Read full article. 1. Zacks Small Cap Research. May 30, 2023 at 8:00 AM ...Zacks Rank N/A INBS: Australia Off to a Strong Start Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 5, 2023 312-265-9588 / [email protected] ESTIMATES Revenue ns of USD) Q1 Q2 Q3 Q4 YearORMP: Data from NASH Phase 2 Study – Positive Takeaways . 11/21/2022. Download (opens in new window)

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

May 30, 2023 · 1. Strong Balance Sheet – MediciNova exited the first quarter of 2023 with approximately $55.3 million in cash and cash equivalents. Due to a low operating cash burn rate, we estimate this is enough to fund operations for at least the next four years. The financial markets continue to be difficult for small-cap biotech companies, and those ... Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 1, 2021 Raising Estimates as Q2 Comes in Way Above Expectations and Company Turns a Profit Compared to its peers in the fintech space who trade at an average of 14.9 times Nov 16, 2023 · Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ... By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT We are initiating coverage of Abeona Therapeutics Inc. (NASDAQ:ABEO) with a valuation of $10.00. Abeona is a biopharmaceutical company developing cell and gene therapies for rare genetic diseases. Its lead clinical program, EB-101, is an autologous cell therapy in development for the treatment of recessive dystrophic epidermolysisBy Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a 78.9% increase from the prior year period. Unit volume was 6,050 vehicles in theSUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Advancing Multiple Clinical Trials in 2023 ESSA Pharma Inc (NASDAQ:EPIX) is developing EPI-7386 as a treatment for prostate cancer. It is a member of a novel class of compounds known as ‘anitens’, which specifically target the androgen …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as importantly, the company has reduced its ...Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. _____ 1. BioLineRx Corporate Website, Accessed September 2023.By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 knows the company well, in our view.ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other …

David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 1, 2021 Raising Estimates as Q2 Comes in Way Above Expectations and Company Turns a Profit Compared to its peers in the fintech space who trade at an average of 14.9 times A new baseball hat tends to be stiff and uncomfortable, and many people prefer the look of an worn-in hat. Fortunately, fading and distressing a baseball cap is quite easy to do. To prepare for the fading process, wet the bill of the hat.Financial Results. In its latest fiscal quarter ending December 31 st, IBS generated total revenues of $626,000 compared to $178,000 in the prior year period. 2Q:23 revenues included a component from both Intelligent Fingerprinting (IFP) and government support revenue while 2Q:22 revenues only included the government support component ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remainedOn May 9, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 2022 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. In the last six weeks, Lantern has dosed its first patient in the Phase II Harmonic study, announced receipt of a patent allowance by the USPTO …Zacks Small Cap Research. TENX: Prioritizing Levosimendan. Read full article. Zacks Small Cap Research. May 22, 2023 at 6:44 AM ...Nov 18, 2022 · OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as importantly, the company has reduced its ...

CXW intends to redeem the $153.9 million outstanding of its 4.625% senior notes that mature in 2023 in full on February 1, 2023, using a combination of cash on hand and existing capacity under its revolving credit facility. CXW had $185.3 million of cash at the end of 3Q22 and its $250.0 million revolver was undrawn.

On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.

The Morningstar US Small Cap Extended Index comprises of small-capitalization U.S. equities. The ETF return is roughly 10.19% so far this year and is up …Find top rated mutual funds and information to help you beat the market. Explore mutual fund resources, portfolios, and mutual fund commentary at Zacks.On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Update on Phase 1 Trial of EPI-7386. ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen therapy ( NCT04421222 ).The following slide gives an overview of the planned early stage clinical trials for CF-370 following submission of the IND, which we expect to occur in the third quarter of 2023. While a Phase 2 proof-of-concept trial is currently planned in patients with cystic fibrosis, the broad spectrum activity of CF-370 means it could likely be used for ...Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Reviva RECOVER Topline Results Data Presentation, October 30, 2023.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …DIREXION DAILY SMALL CAP BULL 3X SHARES. The Direxion Daily Small Cap Bull 3x Shares seeks daily investment results, before fees and expenses, of 300% of the performance of the Russell 2000 Index ...

By John Vandermosten, CFA. NYSE:NHWK. READ THE FULL NHWK RESEARCH REPORT. The recently renamed NightHawk Biosciences, Inc. (NYSE:NHWK) reported first quarter 2022 results on May 16, 2022 and filed its Form 10-Q with the SEC. It has been a whirlwind year for the company as it made an acquisition, expanded its …Apr 1, 2021 · By John Vandermosten, CFA NASDAQ:RVPH RP5063: Retroactive Comparison Against 32 Antipsychotics An estimated 0.25% to 1% of the global population suffers from schizophrenia. To address this estimated 20 million individuals with the chronic disorder there are numerous antipsychotics approved for use. However, a high discontinuation rate due to suboptimal efficacy and serious side effects reveals an May 4, 2023 · First Quarter 2023 Financial and Operational Results. For the quarter ending March 31, 2023, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.8 million vs. $1.9 million in the prior year quarter. This represents growth of nearly 50%, driven by increases in the VA/DOD segment and commercial revenues augmented by electroCore’s ... Instagram:https://instagram. cryptocurrency news shibatexas pacific land stockcharting software for stockscheap motorcycle insurance florida On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022. betting on maddenbest cannabis stocks SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting … total energy services By David Bautz, PhD. NASDAQ:MDNA. READ THE FULL MDNA RESEARCH REPORT. Business Update. Update on ABILITY Trial. Medicenna Therapeutics Corp. (NASDAQ:MDNA) is currently conducting the Phase 1/2 ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study) of MDNA11 in patients with advanced solid …By David Bautz, PhD. NASDAQ:KMDA. READ THE FULL KMDA RESEARCH REPORT. Financial Update. On March 15, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the fourth quarter and full year 2022 and provided a business update. Kamada reported revenues of $129.3 million, which met the …Steven Ralston, CFA, is a Senior Analyst and Director of Research with Zacks Small-Cap Research, with over 30 years of experience in the securities and investment industry. He has covered companies within the Basic/Precious Materials, Industrials, Energy, Biotechnology, Real Estate, Cannabis, Packaged Foods, Consumer and Financial …